In CRC, Ropivacaine, an anesthetic drug, decreased the expression of ITGB1 and affected the phosphorylation of AKT/FAK/ERK, a downstream pathway of ITGB1, serving as a tumor suppressor and thereby decreasing the development and progression of CRC [165]. The gene discussed is AKT1; the disease is colorectal carcinoma.